<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684459</url>
  </required_header>
  <id_info>
    <org_study_id>MCART-002</org_study_id>
    <nct_id>NCT04684459</nct_id>
  </id_info>
  <brief_title>Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis</brief_title>
  <official_title>Phase I Study of Specific CAR-T Dual-targeting HER2 and PD-L1 in Patients With Pleural or Peritoneal Metastasis of HER2 Positive Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serosal cavity metastasis of malignant tumor is one of the late complications, which&#xD;
      seriously affects the quality of life and survival time of patients. HER-2 is frequently&#xD;
      expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant&#xD;
      tumors. The HER-2/PD-L1 dual-targeting CAR-T will be investigated in patients with HER2&#xD;
      positive solid tumor serosal cavity metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>AE during the first 28 days after CAR-T cell administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>12 months</time_frame>
    <description>Baseline up to 28 days after CAR-T cells infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR（objective response rate）</measure>
    <time_frame>Month 1，month 3, month 6</time_frame>
    <description>Include CR（complete response）and PR（partial response）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR (duration of response)</measure>
    <time_frame>12 months</time_frame>
    <description>The time from achievement of disease control</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Peritoneal Carcinoma Metastatic</condition>
  <condition>Pleural Effusion, Malignant</condition>
  <arm_group>
    <arm_group_label>CAR-T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual-targeting HER2 and PD-L1 CAR-T cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dual-targeting HER2 and PD-L1 CAR-T cells</intervention_name>
    <description>serosal cavity infusion</description>
    <arm_group_label>CAR-T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, Age 18-65 years old;&#xD;
&#xD;
          2. Estimated life expectancy ≥ 3 months (according to investigator's judgement);&#xD;
&#xD;
          3. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2;&#xD;
&#xD;
          4. Patients diagnosed as ovarian cancer, non-small cell lung cancer, breast cancer,&#xD;
             gastric cancer, etc., accompanied by serous cavity metastasis, have received systemic&#xD;
             standard treatment, and have clinical symptoms of serous cavity metastasis;&#xD;
&#xD;
          5. Expressing HER2 &gt;20% of primary tumors or metastatic cells in the serous cavity by&#xD;
             immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH);&#xD;
&#xD;
          6. Absolute neutrophil count ≥ 1×10^9/L, platelet count ≥ 75×10^9/L, absolute lymphocyte&#xD;
             count ≥1×10^8/L, hemoglobin ≥ 9.0 g/dl;&#xD;
&#xD;
          7. Creatinine clearance rate ≥60ml/min, Serum ALT/AST≤2.5 times of the normal level, and&#xD;
             total bilirubin≤1.5 times of the normal level;&#xD;
&#xD;
          8. Cardiac ejection fraction ≥50%, no pericardial effusion;&#xD;
&#xD;
          9. No other serious diseases (autoimmune diseases or any immune deficiency disease or&#xD;
             other disease in need of immunosuppressive therapy);&#xD;
&#xD;
         10. Patients must stop chemotherapy and targeted therapy for at least 3 weeks before&#xD;
             starting treatment;&#xD;
&#xD;
         11. Patients must take reliable contraceptive measures before entering the trial, during&#xD;
             the research process until 1 year after CAR-T infusion; reliable contraceptive&#xD;
             measures will be determined by the main investigator or designated personnel;&#xD;
&#xD;
         12. Voluntarily participate in the research, understand and sign the informed consent;&#xD;
&#xD;
         13. The side effect of the last anti-tumor treatment was reduced to ≤1 grade, except for&#xD;
             hair loss.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to cytokines;&#xD;
&#xD;
          2. Uncontrolled activity infection;&#xD;
&#xD;
          3. Acute or chronic (graft-versus-host disease) GVHD;&#xD;
&#xD;
          4. Accompanied by other uncontrolled malignant tumors;&#xD;
&#xD;
          5. Patient with hepatitis B or C active period, HIV infection ≥ the upper limit of the&#xD;
             normal level;&#xD;
&#xD;
          6. Suffer from serious diseases such as coronary heart disease, angina pectoris,&#xD;
             myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, etc.;&#xD;
&#xD;
          7. Patients with grade 2-3 hypertension or poorly controlled;&#xD;
&#xD;
          8. History of mental illness that is difficult to control;&#xD;
&#xD;
          9. Patients have used immunosuppressive agents for a long time after organ&#xD;
             transplantation, except for recent or current inhaled corticosteroid therapy;&#xD;
&#xD;
         10. The existing medical history or mental state history or laboratory abnormalities may&#xD;
             increase the risk associated with participating in the study or the administration of&#xD;
             the study drug;&#xD;
&#xD;
         11. Unstable pulmonary embolism, deep venous embolism or other major arterial/venous&#xD;
             thromboembolic events occurred within 6 months before enrollment. If receiving&#xD;
             anticoagulant therapy;&#xD;
&#xD;
         12. Pregnant or nursing women, or plan to become pregnant during the treatment period or&#xD;
             within 1 year after the treatment ends;&#xD;
&#xD;
         13. Patient suffering from diseases that have signed written informed consent or comply&#xD;
             with research procedures; or are unwilling or unable to comply with research&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Yongsheng Wang</investigator_full_name>
    <investigator_title>Director of Institute of Drug Clinical Trial of West China Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

